Skip to main content
About BRAF V600E

NSCLC is a common type of lung cancer. When it is metastatic (mNSCLC), the cancer cells have spread beyond the lungs to other parts of the body. It can travel through the bloodstream to distant parts of the body, most often to the brain, bones, liver, and adrenal glands.

Gene changes (mutations) have been linked to cancer growth in mNSCLC. In some cases, health care providers may be able to identify specific non-inherited genetic mutations through biomarker testing. With this information, your health care provider may be able to use a therapy specific for your cancer and its mutation(s). Your health care provider can test for BRAF V600E, which is a specific mutation found in mNSCLC and other types of cancer. Approximately 2000 to 3000 people with mNSCLC in the United States may be diagnosed with an abnormal BRAF V600E genetic mutation each year.


What are biomarkers?

To get a treatment that is specific to your type of cancer, your health care provider will want to test for and determine the biomarker of your cancer. Biomarkers represent specific traits within your cancer. If you have a non-inherited genetic mutation, a certain biomarker can alert your health care provider to it.

Mutated gene icon

BRAF V600E is a mutation in the BRAF gene

  • The BRAF gene makes a protein that is involved in sending signals in cells and in cell growth  

  • The BRAF gene may increase the growth and spread of cancer cells

  • This BRAF mutation may be found in some types of cancer, including lung

  • Approximately 2000 to 3000 people with mNSCLC in the United States may be diagnosed with an abnormal BRAF V600E genetic mutation each year

Approximately 2000 to 3000 people with mNSCLC in the United States may be diagnosed with an abnormal BRAF V600E genetic mutation each year
Ask about biomarker testing today

The results of your test can help you and your health care provider find a treatment that is specific for your type of cancer. Ask your health care provider about taking a comprehensive biomarker test.

Important Safety Information

TAFINLAR and MEKINIST may cause serious side effects, including:

Risk of new cancers. TAFINLAR, when used in combination with MEKINIST, may cause a type of skin cancer called cutaneous squamous cell carcinoma, keratoacanthoma, basal cell carcinoma, or melanoma. Talk with your health care provider about your risk for these cancers. Check your skin and tell your health care provider right away about any skin changes, including a new wart, skin sore, or reddish bump that bleeds or does not heal, or a change in size or color of a mole.

Your health care provider should check your skin before you start treatment, and every 2 months while on treatment, to look for any new skin cancers. Your health care provider should continue to check your skin for 6 months after you stop taking TAFINLAR and MEKINIST.

Approved Uses

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to treat people with a type of skin cancer called melanoma:

  • that has spread to other parts of the body (metastatic) or cannot be removed by surgery (unresectable), and

  • that has a certain type of abnormal “BRAF” (V600E or V600K mutation-positive) gene

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to help prevent melanoma that has a certain type of abnormal “BRAF” gene from coming back after the cancer has been removed by surgery.

Click or scroll to see IMPORTANT SAFETY INFORMATION AND APPROVED USES